Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Clin Lung Cancer. 2019 Nov 25;21(1):21–27.e5. doi: 10.1016/j.cllc.2019.07.008

Table 3.

QTc-prolonging medication prescriptions by risk classification and time period

Prevalence of prescriptions (%)
TdP Risk Classification Up to 3 months prior to or at Cohort Entry Date Up to 6 months prior to or at Cohort Entry Date Up to 12 months prior to or at Cohort Entry Date
Known Risk 22.1 26 30.6
Possible Risk 9.9 11.3 13.3
Conditional Risk 38.1 40.9 44.1
Undetermined 30.3 32.8 35.3
Known or Possible 28.4 32.6 37.3
Any 59.9 63 66